Curriculum Vitae: Zhencong Chen, MD

Post-doctoral

Department of Thoracic Surgery,

Zhongshan Hospital, Fudan University

Shanghai, China

Tel: +86-15221918769

Email: zcchen13@fudan.edu.cn



H-index:18

Education and Work Background

2021/07 ----present, post-doctoral

Department of Thoracic Surgery, Zhongshan Hospital, Fudan University

2019/09 ----2021/06, Degree: M.D

Department of Thoracic Surgery, Zhongshan Hospital, Fudan University

Major: Surgery Supervisor: Prof. Qun Wang

2013/9----2019/06, Degree: B.S.Med.

Shanghai Medical College, Fudan University

Major: Clinical Medicine

Academic Positions

- Associate Editor of *Burns & Trauma* (IF:5.71) (2021/11- present)
- Associate Editor of European Journal of Medical Research (IF: 4.981) (2022/10-present)
- Associate Editor of *Chinese Journal of Cancer Research* (IF:4.06) (2023/03-present)
- Associate Editor of *BMC Pulmonary Medicine* (IF:3.32) (2020/07- present)

Chinese Journal of Cancer Research

• Reviewer of Annals of Translational Medicine, Burns & Trauma, BMC

Pulmonary Medicine, Peer J, Journal of Immunology Research, Disease Marker,

etc.

Major Achievements

Foundation

- Presided a Natural Science Foundation of Shanghai, Study on the mechanism of SPP1/METTL3/STING axis regulating tumor -related macrophage -related macrophages to promote the progress of lung adenocarcinoma, 2022.04 2025.04.
- Presided a **Research Foundation of Fellowship of China Postdoctoral Science Foundation**, Study on the mechanism of SPP1/METTL3/STING axis regulating tumor -related macrophage -related macrophages to promote the progress of lung adenocarcinoma, 2022.06 2025.06.

Patents

- Zhencong Chen, et al. Application of gene marker in distinguishing lung adenocarcinoma stem tumor cells from other tumor cells. (Under Review)
- JiaQi Liang, **Zhencong Chen**, et al. Application of gene marker in distinguishing lung adenocarcinoma tumor cells. 2021/10. China

Major Publications (First or Co-first author)

- [1] Landscape and dynamics of single tumor and immune cells in early and advanced-stage lung adenocarcinoma. Clin Transl Med. 2021 Mar;11(3): e350.
- [2] Dissecting the single-cell transcriptome network underlying esophagus non-malignant tissues and esophageal squamous cell carcinoma[J]. EBioMedicine.2021 Jul;69:103459.
- [3] LncRNA FAM83A-AS1 facilitates tumor proliferation and the migration via the HIF-1α/ glycolysis axis in lung adenocarcinoma. Int J Biol Sci. 2022 Jan

- 1;18(2):522-535.
- [4] Dissecting the single-cell transcriptome network in patients with esophageal squamous cell carcinoma receiving operative paclitaxel plus platinum chemotherapy. Oncogenesis. 2021 Oct 26;10(10):71.
- [5] HIF-1α switches the functionality of TGF-β signaling via changing the partners of smads to drive glucose metabolic reprogramming in non-small cell lung cancer. J Exp Clin Cancer Res. 2021 Dec 20;40(1):398.
- [6] Cisplatin resistance-related multi-omics differences and the establishment of machine learning models. J Transl Med. 2022 Apr 11;20(1):171.
- [7] Identification and validation of tumor environment phenotypes in lung adenocarcinoma by integrative genome-scale analysis. Cancer Immunol Immunother. 2020 Jul;69(7):1293-1305.
- [8] Ligand-receptor interaction atlas within and between tumor cells and T cells in lung adenocarcinoma. Int J Biol Sci. 2020 May 18;16(12):2205-2219.
- [9] Identification of differentially expressed genes in lung adenocarcinoma cells using single-cell RNA sequencing not detected using traditional RNA sequencing and microarray. Lab Invest. 2020 Oct;100(10):1318-1329.
- [10] Individualized surgical treatment for patients with tumours of the cervicothoracic junction. Interact Cardiovasc Thorac Surg. 2022 Jun 1;34(6):1024-1030.